25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

GeneFerm Biotechnology Co Ltd
Buy, Hold or Sell?

Let's analyze Geneferm together

I guess you are interested in GeneFerm Biotechnology Co Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of GeneFerm Biotechnology Co Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about GeneFerm Biotechnology Co Ltd

I send you an email if I find something interesting about GeneFerm Biotechnology Co Ltd.

1. Quick Overview

1.1. Quick analysis of Geneferm (30 sec.)










1.2. What can you expect buying and holding a share of Geneferm? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.05
When do you have the money?
1 year
How often do you get paid?
56.3%

What is your share worth?

Current worth
NT$19.20
Expected worth in 1 year
NT$18.02
How sure are you?
81.3%

+ What do you gain per year?

Total Gains per Share
NT$0.30
Return On Investment
0.6%

For what price can you sell your share?

Current Price per Share
NT$49.25
Expected price per share
NT$43.95 - NT$53.74
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Geneferm (5 min.)




Live pricePrice per Share (EOD)
NT$49.25
Intrinsic Value Per Share
NT$23.40 - NT$28.36
Total Value Per Share
NT$42.60 - NT$47.56

2.2. Growth of Geneferm (5 min.)




Is Geneferm growing?

Current yearPrevious yearGrowGrow %
How rich?$24.5m$25.3m$629.8k2.4%

How much money is Geneferm making?

Current yearPrevious yearGrowGrow %
Making money$254.1k$925.6k-$671.5k-264.2%
Net Profit Margin3.1%15.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Geneferm (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Geneferm?

Welcome investor! Geneferm's management wants to use your money to grow the business. In return you get a share of Geneferm.

First you should know what it really means to hold a share of Geneferm. And how you can make/lose money.

Speculation

The Price per Share of Geneferm is NT$49.25. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Geneferm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Geneferm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$19.20. Based on the TTM, the Book Value Change Per Share is NT$-0.30 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.35 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.37 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Geneferm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps0.000.0%0.010.0%0.030.1%0.010.0%0.010.0%
Usd Book Value Change Per Share0.000.0%-0.010.0%0.010.0%0.040.1%0.040.1%
Usd Dividend Per Share0.000.0%0.010.0%0.010.0%0.010.0%0.010.0%
Usd Total Gains Per Share0.000.0%0.000.0%0.020.0%0.050.1%0.050.1%
Usd Price Per Share1.94-2.25-2.50-1.74-1.74-
Price to Earnings Ratio-108.46--25.92-26.92-15.93-15.93-
Price-to-Total Gains Ratio-633.15--89.04-40.42-9.41-9.41-
Price to Book Ratio3.29-3.60-4.10-3.08-3.08-
Price-to-Total Gains Ratio-633.15--89.04-40.42-9.41-9.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.5169
Number of shares659
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.01
Usd Book Value Change Per Share-0.010.04
Usd Total Gains Per Share0.000.05
Gains per Quarter (659 shares)1.5331.73
Gains per Year (659 shares)6.12126.93
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
130-24-42997117
260-48259195244
391-72888292371
4121-9614118390498
5151-12020147487625
6181-14426177585752
7211-16932206682879
8242-193382367791006
9272-217442658771133
10302-241502959741260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%10.02.00.083.3%14.02.00.087.5%14.02.00.087.5%14.02.00.087.5%
Book Value Change Per Share2.02.00.050.0%9.03.00.075.0%13.03.00.081.3%13.03.00.081.3%13.03.00.081.3%
Dividend per Share1.00.03.025.0%6.00.06.050.0%9.00.07.056.3%9.00.07.056.3%9.00.07.056.3%
Total Gains per Share2.02.00.050.0%9.03.00.075.0%13.03.00.081.3%13.03.00.081.3%13.03.00.081.3%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of GeneFerm Biotechnology Co Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.100-0.297+198%0.345-129%1.200-108%1.200-108%
Book Value Per Share--19.20120.218-5%19.787-3%17.859+8%17.859+8%
Current Ratio--2.3532.066+14%1.180+99%2.166+9%2.166+9%
Debt To Asset Ratio--0.3570.304+17%0.311+15%0.378-5%0.378-5%
Debt To Equity Ratio--0.5560.443+25%0.454+23%0.665-16%0.665-16%
Dividend Per Share---0.372-100%0.249-100%0.363-100%0.363-100%
Eps---0.1450.197-174%0.821-118%0.433-134%0.433-134%
Free Cash Flow Per Share---0.1470.441-133%-0.213+44%-0.148+0%-0.148+0%
Free Cash Flow To Equity Per Share--1.3020.554+135%-0.202+116%-0.224+117%-0.224+117%
Gross Profit Margin--2.8421.462+94%0.865+229%1.082+163%1.082+163%
Intrinsic Value_10Y_max--28.361--------
Intrinsic Value_10Y_min--23.403--------
Intrinsic Value_1Y_max--0.096--------
Intrinsic Value_1Y_min--0.093--------
Intrinsic Value_3Y_max--2.382--------
Intrinsic Value_3Y_min--2.232--------
Intrinsic Value_5Y_max--7.190--------
Intrinsic Value_5Y_min--6.494--------
Market Cap2041905000.000-28%2616126000.0003047519058.100-14%3376699548.200-23%2342228776.575+12%2342228776.575+12%
Net Profit Margin---0.0520.031-267%0.156-133%0.102-151%0.102-151%
Operating Margin---0.0690.043-258%0.189-136%0.131-153%0.131-153%
Operating Ratio--1.0690.964+11%0.814+31%1.186-10%1.186-10%
Pb Ratio2.565-28%3.2863.603-9%4.103-20%3.076+7%3.076+7%
Pe Ratio-84.656+22%-108.463-25.923-76%26.924-503%15.928-781%15.928-781%
Price Per Share49.250-28%63.10073.100-14%81.250-22%56.344+12%56.344+12%
Price To Free Cash Flow Ratio-83.548+22%-107.0432.782-3947%-19.507-82%5.413-2077%5.413-2077%
Price To Total Gains Ratio-494.181+22%-633.154-89.039-86%40.420-1666%9.409-6829%9.409-6829%
Quick Ratio--1.4711.244+18%0.829+77%0.712+107%0.712+107%
Return On Assets---0.0050.007-171%0.025-120%0.014-134%0.014-134%
Return On Equity---0.0080.009-185%0.036-121%0.022-134%0.022-134%
Total Gains Per Share---0.1000.075-232%0.595-117%1.563-106%1.563-106%
Usd Book Value--24519695.20025953935.700-6%25324075.700-3%22853278.525+7%22853278.525+7%
Usd Book Value Change Per Share---0.003-0.009+198%0.011-129%0.037-108%0.037-108%
Usd Book Value Per Share--0.5910.623-5%0.609-3%0.550+8%0.550+8%
Usd Dividend Per Share---0.011-100%0.008-100%0.011-100%0.011-100%
Usd Eps---0.0040.006-174%0.025-118%0.013-134%0.013-134%
Usd Free Cash Flow---188188.000568698.900-133%-274073.800+46%-188305.425+0%-188305.425+0%
Usd Free Cash Flow Per Share---0.0050.014-133%-0.007+44%-0.005+0%-0.005+0%
Usd Free Cash Flow To Equity Per Share--0.0400.017+135%-0.006+116%-0.007+117%-0.007+117%
Usd Market Cap62890674.000-28%80576680.80093863586.989-14%104002346.085-23%72140646.319+12%72140646.319+12%
Usd Price Per Share1.517-28%1.9432.251-14%2.503-22%1.735+12%1.735+12%
Usd Profit---185724.000254123.100-173%925624.700-120%522387.250-136%522387.250-136%
Usd Revenue--3569874.0004715526.200-24%5790307.600-38%4583398.050-22%4583398.050-22%
Usd Total Gains Per Share---0.0030.002-232%0.018-117%0.048-106%0.048-106%
 EOD+3 -5MRQTTM+11 -25YOY+12 -245Y+19 -1710Y+19 -17

3.3 Fundamental Score

Let's check the fundamental score of GeneFerm Biotechnology Co Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-84.656
Price to Book Ratio (EOD)Between0-12.565
Net Profit Margin (MRQ)Greater than0-0.052
Operating Margin (MRQ)Greater than0-0.069
Quick Ratio (MRQ)Greater than11.471
Current Ratio (MRQ)Greater than12.353
Debt to Asset Ratio (MRQ)Less than10.357
Debt to Equity Ratio (MRQ)Less than10.556
Return on Equity (MRQ)Greater than0.15-0.008
Return on Assets (MRQ)Greater than0.05-0.005
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of GeneFerm Biotechnology Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.335
Ma 20Greater thanMa 5048.680
Ma 50Greater thanMa 10048.251
Ma 100Greater thanMa 20051.696
OpenGreater thanClose49.500
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About GeneFerm Biotechnology Co Ltd

GeneFerm Biotechnology Co., Ltd. develops, manufactures, and sells fermented health care products in Taiwan and internationally. The company offers microbial fermentation products, which includes mushrooms, lactic acid bacteria, bacteria, yeast, and algae; bio fermented ingredients, such as nattomena, natto fermented powder, red yeast rice fermented powder, antrodia cinnamomea mycelia powder, cordyceps, reishi mycelia, phellinus linteus mycelia powder, armillaria mellea mycelia powder, beta-glucan powder, fruits and vegetables fermented enzyme, as well as probiotics and peptide ingredients. It also provides private label supplements; packaging equipment; microbial fermentation toll manufacturing and consulting services. The company was founded in 1988 and is headquartered in Tainan City, Taiwan.

Fundamental data was last updated by Penke on 2024-11-02 14:25:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Geneferm earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -5.2% means that NT$-0.05 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is -5.2%. The company is making a loss. -1
  • The TTM is 3.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ-5.2%TTM3.1%-8.3%
TTM3.1%YOY15.6%-12.5%
TTM3.1%5Y10.2%-7.0%
5Y10.2%10Y10.2%0.0%
4.3.1.2. Return on Assets

Shows how efficient Geneferm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.5% Return on Assets means that Geneferm generated NT$0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is -0.5%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.7%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.5%TTM0.7%-1.2%
TTM0.7%YOY2.5%-1.8%
TTM0.7%5Y1.4%-0.7%
5Y1.4%10Y1.4%0.0%
4.3.1.3. Return on Equity

Shows how efficient Geneferm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • -0.8% Return on Equity means Geneferm generated NT$-0.01 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is -0.8%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.9%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-0.8%TTM0.9%-1.6%
TTM0.9%YOY3.6%-2.8%
TTM0.9%5Y2.2%-1.3%
5Y2.2%10Y2.2%0.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of GeneFerm Biotechnology Co Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Geneferm is operating .

  • Measures how much profit Geneferm makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -6.9% means the company generated NT$-0.07  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is -6.9%. The company is operating very inefficient. -2
  • The TTM is 4.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM4.3%-11.2%
TTM4.3%YOY18.9%-14.6%
TTM4.3%5Y13.1%-8.7%
5Y13.1%10Y13.1%0.0%
4.3.2.2. Operating Ratio

Measures how efficient Geneferm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.07 means that the operating costs are NT$1.07 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is 1.069. The company is inefficient in keeping operating costs low. -1
  • The TTM is 0.964. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ1.069TTM0.964+0.105
TTM0.964YOY0.814+0.149
TTM0.9645Y1.186-0.222
5Y1.18610Y1.1860.000
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of GeneFerm Biotechnology Co Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Geneferm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.35 means the company has NT$2.35 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is 2.353. The company is able to pay all its short-term debts. +1
  • The TTM is 2.066. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.353TTM2.066+0.287
TTM2.066YOY1.180+0.886
TTM2.0665Y2.166-0.099
5Y2.16610Y2.1660.000
4.4.3.2. Quick Ratio

Measures if Geneferm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.47 means the company can pay off NT$1.47 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is 1.471. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.244. The company is just able to pay all its short-term debts with the most liquid assets.
Trends
Current periodCompared to+/- 
MRQ1.471TTM1.244+0.226
TTM1.244YOY0.829+0.416
TTM1.2445Y0.712+0.532
5Y0.71210Y0.7120.000
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of GeneFerm Biotechnology Co Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Geneferm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Geneferm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.36 means that Geneferm assets are financed with 35.7% credit (debt) and the remaining percentage (100% - 35.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is 0.357. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.304. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.357TTM0.304+0.053
TTM0.304YOY0.311-0.007
TTM0.3045Y0.378-0.074
5Y0.37810Y0.3780.000
4.5.4.2. Debt to Equity Ratio

Measures if Geneferm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 55.6% means that company has NT$0.56 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The MRQ is 0.556. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.443. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.556TTM0.443+0.112
TTM0.443YOY0.454-0.010
TTM0.4435Y0.665-0.222
5Y0.66510Y0.6650.000
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Geneferm generates.

  • Above 15 is considered overpriced but always compare Geneferm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -108.46 means the investor is paying NT$-108.46 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The EOD is -84.656. Based on the earnings, the company is expensive. -2
  • The MRQ is -108.463. Based on the earnings, the company is expensive. -2
  • The TTM is -25.923. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-84.656MRQ-108.463+23.807
MRQ-108.463TTM-25.923-82.540
TTM-25.923YOY26.924-52.847
TTM-25.9235Y15.928-41.851
5Y15.92810Y15.9280.000
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The EOD is -83.548. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -107.043. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 2.782. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-83.548MRQ-107.043+23.495
MRQ-107.043TTM2.782-109.825
TTM2.782YOY-19.507+22.289
TTM2.7825Y5.413-2.631
5Y5.41310Y5.4130.000
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Geneferm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 3.29 means the investor is paying NT$3.29 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of GeneFerm Biotechnology Co Ltd:

  • The EOD is 2.565. Based on the equity, the company is underpriced. +1
  • The MRQ is 3.286. Based on the equity, the company is fair priced.
  • The TTM is 3.603. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.565MRQ3.286-0.721
MRQ3.286TTM3.603-0.317
TTM3.603YOY4.103-0.500
TTM3.6035Y3.076+0.527
5Y3.07610Y3.0760.000
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-06-302023-09-302023-12-312024-03-312024-06-30
Tax Provision  11,044-2,6228,422-6,6911,731-975756-1,354-598
Income Tax Expense  11,044-2,6228,422-6,6911,731-975756-1,354-598



6.2. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in TWD. All numbers in thousands.

Summary
Total Assets1,238,667
Total Liabilities442,573
Total Stockholder Equity796,094
 As reported
Total Liabilities 442,573
Total Stockholder Equity+ 796,094
Total Assets = 1,238,667

Assets

Total Assets1,238,667
Total Current Assets485,015
Long-term Assets753,652
Total Current Assets
Cash And Cash Equivalents 240,536
Net Receivables 62,609
Inventory 172,512
Other Current Assets 9,358
Total Current Assets  (as reported)485,015
Total Current Assets  (calculated)485,015
+/-0
Long-term Assets
Property Plant Equipment 739,580
Long-term Assets Other 3,379
Long-term Assets  (as reported)753,652
Long-term Assets  (calculated)742,959
+/- 10,693

Liabilities & Shareholders' Equity

Total Current Liabilities206,146
Long-term Liabilities236,427
Total Stockholder Equity796,094
Total Current Liabilities
Short-term Debt 49,003
Short Long Term Debt 42,991
Accounts payable 6,297
Other Current Liabilities 146,511
Total Current Liabilities  (as reported)206,146
Total Current Liabilities  (calculated)244,802
+/- 38,656
Long-term Liabilities
Long term Debt 138,750
Capital Lease Obligations 86,550
Long-term Liabilities Other 17,001
Long-term Liabilities  (as reported)236,427
Long-term Liabilities  (calculated)242,301
+/- 5,874
Total Stockholder Equity
Common Stock414,598
Retained Earnings 47,237
Accumulated Other Comprehensive Income 41,036
Other Stockholders Equity 293,223
Total Stockholder Equity (as reported)796,094
Total Stockholder Equity (calculated)796,094
+/-0
Other
Capital Stock414,598
Cash and Short Term Investments 240,536
Common Stock Shares Outstanding 41,460
Current Deferred Revenue4,335
Liabilities and Stockholders Equity 1,238,667
Net Debt 27,755
Net Invested Capital 977,835
Net Working Capital 278,869
Property Plant and Equipment Gross 739,580
Short Long Term Debt Total 268,291



6.3. Balance Sheets Structured

Currency in TWD. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
970,055
982,576
1,266,666
1,309,813
1,294,470
1,316,883
1,097,685
1,123,701
1,131,047
1,189,632
1,202,991
1,257,444
1,229,916
1,175,375
1,205,783
1,238,667
1,238,6671,205,7831,175,3751,229,9161,257,4441,202,9911,189,6321,131,0471,123,7011,097,6851,316,8831,294,4701,309,8131,266,666982,576970,055
   > Total Current Assets 
535,592
535,576
806,380
803,209
769,245
765,182
463,132
422,428
365,103
13,696
387,257
438,431
405,061
397,132
435,296
485,015
485,015435,296397,132405,061438,431387,25713,696365,103422,428463,132765,182769,245803,209806,380535,576535,592
       Cash And Cash Equivalents 
359,792
348,019
619,072
588,598
549,308
539,611
249,673
182,043
94,455
13,696
87,547
148,047
114,878
120,153
185,706
240,536
240,536185,706120,153114,878148,04787,54713,69694,455182,043249,673539,611549,308588,598619,072348,019359,792
       Short-term Investments 
0
0
30
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000003000
       Net Receivables 
65,828
73,869
71,540
89,545
84,957
104,902
98,449
104,005
120,590
121,439
132,123
119,740
111,015
117,750
83,766
62,609
62,60983,766117,750111,015119,740132,123121,439120,590104,00598,449104,90284,95789,54571,54073,86965,828
       Inventory 
106,391
109,515
111,943
120,743
131,268
114,832
109,947
126,419
143,374
142,605
157,042
164,173
173,255
155,434
158,291
172,512
172,512158,291155,434173,255164,173157,042142,605143,374126,419109,947114,832131,268120,743111,943109,515106,391
   > Long-term Assets 
434,463
447,000
460,286
506,604
525,225
551,701
634,553
701,273
765,944
816,093
815,734
819,013
824,855
778,243
770,487
753,652
753,652770,487778,243824,855819,013815,734816,093765,944701,273634,553551,701525,225506,604460,286447,000434,463
       Property Plant Equipment 
414,882
421,445
437,230
452,967
497,363
510,385
540,601
550,555
753,371
802,377
801,914
804,792
811,550
764,182
755,727
739,580
739,580755,727764,182811,550804,792801,914802,377753,371550,555540,601510,385497,363452,967437,230421,445414,882
       Other Assets 
18,212
24,326
21,967
52,688
26,812
39,921
92,699
149,602
133,701
359,843
0
19,738
0
0
0
0
000019,7380359,843133,701149,60292,69939,92126,81252,68821,96724,32618,212
> Total Liabilities 
580,615
586,382
575,021
598,289
564,482
569,223
339,779
335,707
317,410
358,861
403,828
412,174
350,169
282,538
403,820
442,573
442,573403,820282,538350,169412,174403,828358,861317,410335,707339,779569,223564,482598,289575,021586,382580,615
   > Total Current Liabilities 
101,056
115,846
408,066
440,872
415,307
431,182
203,508
207,053
195,456
239,217
290,596
299,833
223,085
189,859
217,170
206,146
206,146217,170189,859223,085299,833290,596239,217195,456207,053203,508431,182415,307440,872408,066115,846101,056
       Short-term Debt 
0
0
0
0
0
0
0
0
81,669
115,109
107,859
116,142
116,169
75,930
39,416
49,003
49,00339,41675,930116,169116,142107,859115,10981,66900000000
       Short Long Term Debt 
8,898
11,837
12,815
16,281
14,682
27,481
11,588
21,114
77,684
109,136
101,703
109,639
108,941
69,888
33,146
42,991
42,99133,14669,888108,941109,639101,703109,13677,68421,11411,58827,48114,68216,28112,81511,8378,898
       Accounts payable 
16,743
23,864
21,814
30,560
27,931
39,081
20,153
36,574
19,623
11,793
18,441
8,144
6,521
8,564
9,187
6,297
6,2979,1878,5646,5218,14418,44111,79319,62336,57420,15339,08127,93130,56021,81423,86416,743
       Other Current Liabilities 
13,960
17,133
20,278
37,851
35,427
37,307
117,361
101,722
78,787
104,690
141,004
161,190
91,975
99,589
164,735
146,511
146,511164,73599,58991,975161,190141,004104,69078,787101,722117,36137,30735,42737,85120,27817,13313,960
   > Long-term Liabilities 
479,559
470,536
166,955
157,417
149,175
138,041
136,271
128,654
121,954
119,644
113,232
112,341
127,084
92,679
186,650
236,427
236,427186,65092,679127,084112,341113,232119,644121,954128,654136,271138,041149,175157,417166,955470,536479,559
       Long term Debt 
367,753
359,911
57,366
49,050
41,500
31,250
24,333
17,417
10,500
5,250
0
0
0
0
87,500
138,750
138,75087,50000005,25010,50017,41724,33331,25041,50049,05057,366359,911367,753
       Capital Lease Obligations Min Short Term Debt
103,690
102,254
100,930
99,519
98,781
97,319
101,405
99,860
17,835
-10,336
-4,300
-13,643
1,694
6,261
48,810
37,547
37,54748,8106,2611,694-13,643-4,300-10,33617,83599,860101,40597,31998,78199,519100,930102,254103,690
       Other Liabilities 
13,533
13,758
13,985
14,211
14,437
14,664
15,395
15,527
15,935
15,594
0
16,345
0
0
0
0
000016,345015,59415,93515,52715,39514,66414,43714,21113,98513,75813,533
       Long-term Liabilities Other 
13,533
13,758
13,985
14,211
14,437
14,664
14,893
15,127
15,360
15,594
15,829
16,063
16,297
16,530
16,768
17,001
17,00116,76816,53016,29716,06315,82915,59415,36015,12714,89314,66414,43714,21113,98513,75813,533
> Total Stockholder Equity
389,440
396,194
691,645
711,524
729,988
747,660
757,906
787,994
813,637
830,771
799,163
845,270
879,747
892,837
801,963
796,094
796,094801,963892,837879,747845,270799,163830,771813,637787,994757,906747,660729,988711,524691,645396,194389,440
   Common Stock
278,934
278,934
404,204
407,894
407,894
407,894
414,598
414,598
414,598
414,598
414,598
414,598
414,598
414,598
414,598
414,598
414,598414,598414,598414,598414,598414,598414,598414,598414,598414,598407,894407,894407,894404,204278,934278,934
   Retained Earnings 
12,158
18,243
26,190
36,593
54,809
72,268
51,310
81,329
86,012
103,471
71,750
109,981
143,841
157,324
66,094
47,237
47,23766,094157,324143,841109,98171,750103,47186,01281,32951,31072,26854,80936,59326,19018,24312,158
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
19,804
19,479
19,592
27,468
28,085
27,692
28,048
41,036
41,03628,04827,69228,08527,46819,59219,47919,80400000000
   Capital Surplus 0000000000000000
   Treasury Stock0000000000000000



6.4. Balance Sheets

Currency in TWD. All numbers in thousands.




6.5. Cash Flows

Currency in TWD. All numbers in thousands.




6.6. Income Statements

Currency in TWD. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in TWD. All numbers in thousands.

Gross Profit (+$)
totalRevenue793,770
Cost of Revenue-507,419
Gross Profit286,351286,351
 
Operating Income (+$)
Gross Profit286,351
Operating Expense-133,212
Operating Income157,180153,139
 
Operating Expense (+$)
Research Development28,333
Selling General Administrative61,298
Selling And Marketing Expenses43,581
Operating Expense133,212133,212
 
Net Interest Income (+$)
Interest Income918
Interest Expense-4,173
Other Finance Cost-0
Net Interest Income-3,255
 
Pretax Income (+$)
Operating Income157,180
Net Interest Income-3,255
Other Non-Operating Income Expenses0
Income Before Tax (EBT)153,433160,927
EBIT - interestExpense = 153,007
153,433
128,794
Interest Expense4,173
Earnings Before Interest and Taxes (EBIT)157,180157,606
Earnings Before Interest and Taxes (EBITDA)230,668
 
After tax Income (+$)
Income Before Tax153,433
Tax Provision-28,812
Net Income From Continuing Ops124,621124,621
Net Income124,621
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses640,631
Total Other Income/Expenses Net-3,7473,255
 

Technical Analysis of Geneferm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Geneferm. The general trend of Geneferm is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Geneferm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of GeneFerm Biotechnology Co Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 51.00 < 53.60 < 53.74.

The bearish price targets are: 44.00 > 43.95.

Tweet this
GeneFerm Biotechnology Co Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of GeneFerm Biotechnology Co Ltd. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

GeneFerm Biotechnology Co Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of GeneFerm Biotechnology Co Ltd. The current macd is -0.1277725.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Geneferm price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Geneferm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Geneferm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
GeneFerm Biotechnology Co Ltd Daily Moving Average Convergence/Divergence (MACD) ChartGeneFerm Biotechnology Co Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of GeneFerm Biotechnology Co Ltd. The current adx is 19.99.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Geneferm shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
GeneFerm Biotechnology Co Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of GeneFerm Biotechnology Co Ltd. The current sar is 49.65.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
GeneFerm Biotechnology Co Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of GeneFerm Biotechnology Co Ltd. The current rsi is 53.33. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
GeneFerm Biotechnology Co Ltd Daily Relative Strength Index (RSI) ChartGeneFerm Biotechnology Co Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of GeneFerm Biotechnology Co Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 4/6.
The longshort score for the Stochastic Oscillator is 4/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Geneferm price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
GeneFerm Biotechnology Co Ltd Daily Stochastic Oscillator ChartGeneFerm Biotechnology Co Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of GeneFerm Biotechnology Co Ltd. The current cci is 19.91.

GeneFerm Biotechnology Co Ltd Daily Commodity Channel Index (CCI) ChartGeneFerm Biotechnology Co Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of GeneFerm Biotechnology Co Ltd. The current cmo is 13.25.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
GeneFerm Biotechnology Co Ltd Daily Chande Momentum Oscillator (CMO) ChartGeneFerm Biotechnology Co Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of GeneFerm Biotechnology Co Ltd. The current willr is -35.35353535.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Geneferm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
GeneFerm Biotechnology Co Ltd Daily Williams %R ChartGeneFerm Biotechnology Co Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of GeneFerm Biotechnology Co Ltd.

GeneFerm Biotechnology Co Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of GeneFerm Biotechnology Co Ltd. The current atr is 1.176959.

GeneFerm Biotechnology Co Ltd Daily Average True Range (ATR) ChartGeneFerm Biotechnology Co Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of GeneFerm Biotechnology Co Ltd. The current obv is 13,474,424.

GeneFerm Biotechnology Co Ltd Daily On-Balance Volume (OBV) ChartGeneFerm Biotechnology Co Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of GeneFerm Biotechnology Co Ltd. The current mfi is 53.88.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
GeneFerm Biotechnology Co Ltd Daily Money Flow Index (MFI) ChartGeneFerm Biotechnology Co Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for GeneFerm Biotechnology Co Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-07-03RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-07-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-07-10ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-07-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-22BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-07-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-07-29WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-06ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-08-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-08-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-09-06CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-19SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-20STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-24SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-01STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-10-07DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-16MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-17STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-10-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-10-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-06STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-11-15DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.

6.3. Candlestick Patterns

GeneFerm Biotechnology Co Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of GeneFerm Biotechnology Co Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5053.335
Ma 20Greater thanMa 5048.680
Ma 50Greater thanMa 10048.251
Ma 100Greater thanMa 20051.696
OpenGreater thanClose49.500
Total3/5 (60.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Geneferm with someone you think should read this too:
  • Are you bullish or bearish on Geneferm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Geneferm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about GeneFerm Biotechnology Co Ltd

I send you an email if I find something interesting about GeneFerm Biotechnology Co Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about GeneFerm Biotechnology Co Ltd.

Receive notifications about GeneFerm Biotechnology Co Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.